| 2026-08-11 | Press release | C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-08-10 | Presentation | Our Corporate Presentation |
| 2026-08-10 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-11 | Press release | C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as |
| 2026-05-20 | Press release | C4 Therapeutics to Participate in Upcoming Conferences |
| 2026-05-18 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights |
| 2026-04-09 | Press release | C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and |
| 2026-03-25 | Press release | C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO |
| 2026-03-09 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-26 | Press release | C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-02-23 | Press release | C4 Therapeutics to Participate in Upcoming March Conferences |
| 2026-02-23 | Press release | C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Com |
| 2026-02-09 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-04 | Press release | C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 2026-01-26 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-14 | Press release | C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and D |
| 2025-11-25 | Press release | C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference |
| 2025-10-16 | Press release | C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering |
| 2025-10-01 | Press release | C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomi |
| 2025-09-20 | Press release | C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the Int |
| 2025-09-04 | Press release | C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration |
| 2025-09-03 | Press release | C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma S |
| 2025-02-27 | Press release | C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
| 2025-02-24 | Press release | C4 Therapeutics to Participate in Upcoming March Investor Conferences |
| 2025-01-14 | Press release | C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet |
| 2025-01-08 | Press release | C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 2024-11-20 | Press release | C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors |
| 2024-11-06 | Press release | C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial |
| 2024-11-05 | Press release | C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Ly |
| 2024-10-31 | Press release | C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
| 2024-10-28 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2024-10-15 | Press release | C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, P |
| 2024-10-09 | Press release | C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity |
| 2024-09-30 | Press release | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2024-09-13 | Press release | C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From O |
| 2024-09-10 | Press release | C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen |
| 2024-09-08 | Press release | C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Onc |
| 2024-09-03 | Press release | C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors |
| 2024-08-29 | Press release | C4 Therapeutics to Participate in Upcoming September Investor Conferences |